GlobeNewswire

Decentral Inc. and Gowling WLG Form Strategic Blockchain Alliance

Dela

Collaboration to pave way for responsible growth of Canadian blockchain sector

 

TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- Decentral Inc., Canada's leading blockchain company and the creator of Jaxx, and Gowling WLG, a multinational law firm and leader in the blockchain space, have today announced a strategic alliance to optimize the many commercial and legal applications of blockchain technology. The relationship will allow the two companies to fuse their expertise on a number of significant initiatives - from engineering practical smart contract technology and drafting foundational legal precedents documents, to helping regulators establish frameworks that encourage the responsible growth of Canada's thriving blockchain sector.

Based in Toronto, Decentral is one of Canada's most recognizable blockchain companies. Its Founder and CEO, Anthony Diiorio, co-founded Ethereum. Decentral's flagship product is Jaxx, a cryptocurrency wallet and multi-token blockchain interface.

Diiorio believes the alliance is a sign that the blockchain space is rapidly progressing. "Decentral's relationship with Gowling WLG spans a number of years, and we are delighted to form an alliance that enables us to work even closer together on a number of transformative blockchain industry initiatives. Canada is one of the leaders on the world stage for blockchain and cryptocurrency and I am confident Decentral's strategic alliance with Gowling WLG will further cement the country's place as an innovation hub," said Diiorio.

Usman Sheikh, Head of Gowling WLG's Blockchain & Smart Contracts Group, said:  "Decentral is a major player on the world blockchain stage. As Gowling WLG continues to assert itself as the Canadian legal industry's blockchain torchbearer, our collaboration with Decentral will ensure our clients have access to the cutting-edge tools and forward-looking expertise needed to succeed in an increasingly competitive landscape."

As part of the agreement, Decentral will help Gowling WLG develop its internal blockchain infrastructure and client-facing tools. Gowling WLG will provide comprehensive legal guidance on Decentral's current practices and ongoing projects.

Decentral's President Addison Cameron-Huff said: "This alliance demonstrates Canada's leadership in the blockchain space - a winning combination of a world-class blockchain software team plus a best-of-breed legal team. Together, Gowling WLG and Decentral will help to refine and architect the burgeoning Canadian blockchain industry, lifting the technology to new heights."

ABOUT GOWLING WLG
In recent years, Gowling WLG has distinguished itself as a legal market leader in blockchain. It is a co-founding member of the Blockchain Research Institute, was instrumental in the public listing of the very first blockchain company in the world, and its experts are currently authoring The Law of Blockchain Technology (scheduled for publication by Thomson Reuters in 2018). In October 2017, Gowling WLG officially launched its Blockchain & Smart Contracts Practice Group, comprising lawyers with advanced expertise in securities, intellectual property and tax law, litigation and other key areas.

ABOUT DECENTRAL AND JAXX
Decentral was created by Anthony Diiorio. It's located in the heart of downtown Toronto and has been home to hundreds of blockchain community events. Decentral is primarily focused on Jaxx, the multi-token blockchain interface that provides a unified experience across 8 platforms and devices. The flagship product's strategic approach means Jaxx neither holds nor has access to customer funds. Driven by design and user experience and built with simplicity in mind, Jaxx's mission is to become the interface to the blockchain world.
Download and experience Jaxx through http://jaxx.io/

For more information, contact: 
Usman Sheikh, National Head, Blockchain & Smart Contract Group, Gowling WLG. Tel: +1 416-862-3627. Email: usman.sheikh@gowlingwlg.com 

Anne Gaviola, Content & Communications Lead, Decentral. Tel: 1-888-650-3796. Email: pr@decentral.ca 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Decentral Inc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum